Rio Grande Cancer Specialists

07/07/2025

Struggling with osteoarthritis pain?

At RGCS, there is a non-surgical option that’s helping patient move freely again. At Rio Grande, our Benign Conditions Clinic offers safe outpatient treatments for osteoarthritis of the knees, hands, shoulders, and more using low-dose radiation medicine.

Low-dose radiation medicine is ideal for patients who:

✔️ Can’t have surgery
✔️ Don’t want joint injections
✔️ Haven’t found relief with medication’s

Learn more about about how our high tech treatments can help you reclaim your mobility at rgcshope.com.

10/09/2024

📢 Exciting News! 🌟

We are thrilled to announce that Rio Grande Cancer Specialists offers Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) treatment! 💉✨
Pluvicto is a cutting-edge radiopharmaceutical therapy designed to target and treat advanced prostate cancer, offering new hope to patients. Our team is dedicated to providing the latest and most effective treatments to ensure the best care possible.

🏥 Contact us today to learn more about Pluvicto and how it can be part of your Prostate Cancer treatment plan!

12/20/2023

Rio Grande Cancer Specialists is proud to announce our partnership with Novartis to bring PLUVICTO to West Texas and Southern New Mexico. After months of hard work and dedication, today we delivered the first dose of this new treatment option in El Paso.

PLUVICTO is the first and only approved PSMA-targeted radioligand therapy for men with PSMA positive castrate resistant metastatic prostate cancer. With the introduction of this therapy, RGCS reaffirms its commitment to providing innovative therapy solutions to meet the evolving needs of our patients and community. This is a giant leap forward in enhancing the healthcare standards and addressing challenges in prostate cancer care for West Texas and Southern New Mexico.

Rio Grande Cancer Specialists, providing HOPE through compassionate quality care.

12/01/2023

At Rio Grande Cancer Specialists, we treat the people whose lives are impacted by a cancer diagnosis, but refuse to let themselves be defined by their diagnosis. Offering highly specialized treatment services and options, Rio Grande staff, physicians, volunteers, students, and community partners take pride in bringing HOPE to our patients and their families. HOPE ensures a community in which all people can achieve their full potential for health and well-being. HOPE means we work hard to be trusted by patients, be a valued partner in the community, and be creators of positive change.
RGCS has been providing HOPE to El Paso since 2008. Visit us at rgcshope.com

11/05/2023

Congratulations to Dr. Travis Mendel and the team at the Rio Grande Cancer Specialists for completing their 100th procedure! For more information about Dr. Mendel, visit: https://rgu.us.com/urology/providers/dr-travis-mendel-m-d/
For more information about Rio Grande Cancer Specialists, visit: https://rgcshope.com/

11/05/2023

Very humbled to have heard the amazing story of Dr. Glaucomflecken (aka, Dr. Will Flanary). Bringing some humor to the serious subject of testicular cancer, Dr. Glaucomflecken was a highlighted speaker at the 15th Annual LUGPA meeting. Easily the best line from his talk was "...and then I found a lump on my third testicle".

Grande Cancer Specialists
www.glaucomflecken.com

11/05/2023

Rio Grande Urology and Rio Grande Cancer Specialists are proud to have taken part in the 15th Annual LUGPA meeting in Orlando, Florida. The Large Urology Group Practice Association is the only nonprofit urology trade association in the United States. LUGPA advocates for patients by helping urology practices meet the challenges of the changing healthcare landscape by valuing quality, collaboration, innovation, and integrity. That's why RGU and RGCS are so proud of our continuing relationship with them.

Grande Cancer Specialists

10/31/2023

10/31/2023

Rio Grande Cancer Specialists is proud to have been recognized by our partners at Boston Scientific as a Center of Excellence. SpaceOAR hydrogel has changed prostate cancer care, and allowed RGCS the ability to better target the prostate for dose while minimizing side effects to the re**um.